

Jiangfei Wang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1817641/publications.pdf>

Version: 2024-02-01

31
papers

811
citations

516710

16
h-index

501196

28
g-index

31
all docs

31
docs citations

31
times ranked

1605
citing authors

#	ARTICLE	IF	CITATIONS
1	A Novel TNFSF-Based Signature Predicts the Prognosis and Immunosuppressive Status of Lower-Grade Glioma. <i>BioMed Research International</i> , 2022, 2022, 1-21.	1.9	1
2	Novel roles of VAT1 expression in the immunosuppressive action of diffuse gliomas. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2589-2600.	4.2	5
3	Integrated analysis of the genomic and transcriptional profile of high-grade gliomas in different age groups. <i>Clinical Immunology</i> , 2021, 226, 108719.	3.2	1
4	Single-Cell Atlas Reveals Complexity of the Immunosuppressive Microenvironment of Initial and Recurrent Glioblastoma. <i>Frontiers in Immunology</i> , 2020, 11, 835.	4.8	111
5	Combination of Anti-Programmed Death 1 Therapy and Apatinib for a Patient with Hepatocellular Carcinoma and Brain Metastasis: Case Report and Literature Review. <i>World Neurosurgery</i> , 2020, 143, 114-117.	1.3	1
6	High Dimensional Mass Cytometry Analysis Reveals Characteristics of the Immunosuppressive Microenvironment in Diffuse Astrocytomas. <i>Frontiers in Oncology</i> , 2020, 10, 78.	2.8	18
7	A novel DNA damage response signature of IDH-mutant grade II and grade III astrocytoma at transcriptional level. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 579-591.	2.5	4
8	Prognostic value of a nine-gene signature in glioma patients based on tumor-associated macrophages expression profiling. <i>Clinical Immunology</i> , 2020, 216, 108430.	3.2	18
9	CyTOF Analysis Reveals a Distinct Immunosuppressive Microenvironment in IDH Mutant Anaplastic Gliomas. <i>Frontiers in Oncology</i> , 2020, 10, 560211.	2.8	4
10	Management of brain metastases: history and the present. <i>Chinese Neurosurgical Journal</i> , 2019, 5, 1.	0.9	40
11	Behaviors of Glioblastoma Cells in in Vitro Microenvironments. <i>Scientific Reports</i> , 2019, 9, 85.	3.3	70
12	High expression of VAT1 is a prognostic biomarker and predicts malignancy in glioblastoma. <i>Oncology Reports</i> , 2019, 42, 1422-1430.	2.6	5
13	Quantitative Assessment of Invasion of High-Grade Gliomas Using Diffusion Tensor Magnetic Resonance Imaging. <i>World Neurosurgery</i> , 2018, 113, e561-e567.	1.3	6
14	The pathogenesis shared between abdominal aortic aneurysms and intracranial aneurysms: a microarray analysis. <i>Neurosurgical Review</i> , 2018, 41, 667-674.	2.4	2
15	An immune-related lncRNA signature for patients with anaplastic gliomas. <i>Journal of Neuro-Oncology</i> , 2018, 136, 263-271.	2.9	129
16	Bioinformatic analysis of gene expression and methylation regulation in glioblastoma. <i>Journal of Neuro-Oncology</i> , 2018, 136, 495-503.	2.9	38
17	Regional specificity of 1p/19q co-deletion combined with radiological features for predicting the survival outcomes of anaplastic oligodendroglial tumor patients. <i>Journal of Neuro-Oncology</i> , 2018, 136, 523-531.	2.9	7
18	Severe cerebral abscess associated with pulmonary arteriovenous fistula: case report and literature review. <i>Chinese Neurosurgical Journal</i> , 2018, 4, 30.	0.9	3

#	ARTICLE	IF	CITATIONS
19	Integrated Analysis of LncRNA-mRNA Co-Expression Profiles in Patients with Moyamoya Disease. <i>Scientific Reports</i> , 2017, 7, 42421.	3.3	25
20	Identification of a Long Noncoding RNA-Associated Competing Endogenous RNA Network in Intracranial Aneurysm. <i>World Neurosurgery</i> , 2017, 97, 684-692.e4.	1.3	27
21	Histopathological, molecular, clinical and radiological characterization of rosette-forming glioneuronal tumor in the central nervous system. <i>Oncotarget</i> , 2017, 8, 109175-109190.	1.8	44
22	Aberrant expression of lncRNAs and mRNAs in patients with intracranial aneurysm. <i>Oncotarget</i> , 2017, 8, 2477-2484.	1.8	21
23	LncRNA profile study reveals four-lncRNA signature associated with the prognosis of patients with anaplastic gliomas. <i>Oncotarget</i> , 2016, 7, 77225-77236.	1.8	64
24	A three-gene signature for prognosis in patients with MGMT promoter-methylated glioblastoma. <i>Oncotarget</i> , 2016, 7, 69991-69999.	1.8	37
25	Analysis of Treatment Tolerance and Factors Associated with Overall Survival in Elderly Patients with Glioblastoma. <i>World Neurosurgery</i> , 2016, 95, 77-84.	1.3	18
26	Radiologic Features and Expression of Vascular Endothelial Growth Factor Stratify Survival Outcomes in Patients with Glioblastoma. <i>American Journal of Neuroradiology</i> , 2016, 37, 629-635.	2.4	7
27	Identifying the association between contrast enhancement pattern, surgical resection, and prognosis in anaplastic glioma patients. <i>Neuroradiology</i> , 2016, 58, 367-374.	2.2	18
28	Radiological features combined with IDH1 status for predicting the survival outcome of glioblastoma patients. <i>Neuro-Oncology</i> , 2016, 18, 589-597.	1.2	48
29	Identifying the Association of Contrast Enhancement with Vascular Endothelia Growth Factor Expression in Anaplastic Gliomas: A Volumetric Magnetic Resonance Imaging Analysis. <i>PLoS ONE</i> , 2015, 10, e0121380.	2.5	7
30	ALDH1A3: A Marker of Mesenchymal Phenotype in Gliomas Associated with Cell Invasion. <i>PLoS ONE</i> , 2015, 10, e0142856.	2.5	28
31	Gigantic ossified chronic epidural haematoma and contralateral postoperative subdural haematoma: A case report and literature review. <i>British Journal of Neurosurgery</i> , 2015, 29, 85-86.	0.8	4